Can Doctors Prescribe GLP-1 for Weight Loss? Clinical Criteria

Last reviewed: June 2, 2026

Last updated: June 2, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes, licensed physicians can prescribe GLP-1 receptor agonist medications for weight loss in appropriate candidates. The FDA has approved several GLP-1 drugs specifically for weight management in adults with obesity or overweight with weight-related conditions. However, prescription authority is contingent on medical evaluation, baseline health assessment, and documented clinical rationale.

For patients considering GLP-1 therapy, understanding the provider's decision-making process and eligibility criteria is essential. PlexusDx emphasizes precision-informed care: recognizing that genetic factors in GLP-1 and related metabolic pathways may influence how individual patients respond, enabling more targeted conversations with healthcare providers about treatment fit.

FDA Approval Status and Prescription Authority

The FDA has approved multiple GLP-1 medications for chronic weight management. These include semaglutide (Wegovy), tirzepatide (Zepbound), and liraglutide (Saxenda), among others. Approval requires documented BMI of 30 kg/m² or higher, or BMI of 27 kg/m² with weight-related comorbidities such as hypertension or type 2 diabetes.

Prescription authority resides exclusively with licensed physicians, nurse practitioners, and physician assistants acting under state-specific scope-of-practice regulations. Telemedicine platforms, independent pharmacies, and direct-to-consumer models must operate within these regulatory boundaries. Each prescriber bears responsibility for medical evaluation and ongoing clinical monitoring.

Clinical Eligibility Criteria and Provider Assessment Framework

Providers typically conduct a standardized assessment before prescribing GLP-1 medications. This includes baseline metabolic markers, cardiovascular risk stratification, medication interaction screening, and contraindication assessment. Documentation should reflect medical necessity and individualized treatment rationale aligned with current clinical practice guidelines from endocrinology and obesity medicine societies.

Assessment Component	What Providers Evaluate
BMI and Weight Status	BMI ≥30 or ≥27 with weight-related comorbidities; baseline and trend data
Metabolic Health Markers	Fasting glucose, HbA1c, lipid panel, liver and kidney function
Cardiovascular Risk	History of hypertension, cardiac events, stroke; current medications
Contraindications Screening	Personal/family history of medullary thyroid cancer, MEN 2; pancreatitis history
Medication Interactions	Review of concurrent drugs affecting glucose or cardiovascular function
Renal and Hepatic Function	eGFR and liver enzymes to assess tolerability and dose adjustments
Gastrointestinal History	Gastroparesis, inflammatory bowel disease, or other GI complications

How Genetic Predisposition May Inform Provider Conversations

Recent evidence suggests that genetic variants in GLP-1 receptor (GLP1R) and related metabolic genes may influence individual responsiveness to GLP-1 therapy. Genetic predisposition markers do not predict exact medication response, but they may help contextualize why some individuals experience robust appetite suppression while others require higher doses or alternative approaches.

Understanding your genetic profile in peptide response pathways can support a more informed conversation with your provider about treatment selection and monitoring strategy. For example, certain variants in FTO or MC4R genes relate to appetite regulation and weight biology; recognizing these predispositions may help providers tailor expectations and follow-up protocols rather than assuming a universal dose escalation timeline.

Medical Oversight, Monitoring, and Safety Considerations

Responsible GLP-1 prescription requires ongoing clinical supervision. Providers must schedule follow-up visits to assess efficacy, monitor for adverse effects, and adjust dosing based on individual tolerance and metabolic response. Common side effects—nausea, vomiting, constipation—typically diminish with dose titration, but persistent or severe symptoms warrant dose reduction or medication discontinuation.

Certain patient populations require heightened caution: those with personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, severe renal impairment, or acute pancreatitis should be carefully evaluated before starting GLP-1 therapy. Pregnant or nursing patients are typically excluded. A qualified provider will document contraindications, explain risks and benefits, and establish a monitoring schedule aligned with clinical evidence and patient-specific factors.

Compounded vs. Branded GLP-1 Options: What Prescribers Consider

Providers may prescribe either branded GLP-1 medications (Wegovy, Zepbound, Mounjaro, Saxenda) or compounded formulations from licensed 503A pharmacies. Both require valid prescriptions and clinical evaluation. Compounded medications are subject to state pharmacy board oversight and must meet USP standards for sterility, potency, and labeling but differ in manufacturing and availability.

Cost, formulary coverage, supply availability, and patient preference influence prescriber recommendations. PlexusDx partners with licensed 503A compounding pharmacies to offer compounded semaglutide and tirzepatide options at transparent, commitment-based pricing. Regardless of formulation chosen, medical oversight and dose titration remain the provider's clinical responsibility.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines key variants in GLP1R, GIPR, FTO, and MC4R genes that relate to peptide response pathways and appetite regulation biology. These predispositions may help provide context for individual metabolic traits and treatment considerations, but they should always be interpreted with a qualified healthcare provider rather than as standalone diagnostic tools.

The genetic test does not predict whether you will respond to GLP-1 medication or at what dose. Instead, it reveals predispositions in pathways relevant to peptide signaling and weight regulation. For example, certain FTO variants correlate with increased appetite and BMI in population studies, while MC4R variants relate to melanocortin pathway function. Sharing this information with your provider may support a more personalized treatment conversation.

Integrating genetic insights into your provider consultation can help shift the discussion from generic dosing schedules toward a more individualized approach. Understanding your genetic predispositions in peptide pathways may support informed decisions about treatment selection, monitoring timelines, and realistic expectations—enabling your provider to offer precision-informed care rather than applying assumptions based solely on BMI or clinical presentation.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.